Difference between revisions of "Lung tumours"
Jump to navigation
Jump to search
(rewrite intro) |
m (→Basic pathologic approach to lung cancer: add ref) |
||
| Line 30: | Line 30: | ||
*Most lung cancer fits into one of the above categories. | *Most lung cancer fits into one of the above categories. | ||
*All types may be metastatic. Pathologists usually don't have to sort this out, as the clinican often knows whether a given lesion is metastatic (when correlated with radiology). | *All types may be metastatic. Pathologists usually don't have to sort this out, as the clinican often knows whether a given lesion is metastatic (when correlated with radiology). | ||
*Lung cancers may have a mixed morphology, e.g. SCLS may have squamous component.<ref> | *Lung cancers may have a mixed morphology, e.g. SCLS may have squamous component.<ref name=pmid17684766>{{cite journal |author=Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M |title=Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data |journal=Virchows Arch. |volume=451 Suppl 1 |issue= |pages=S51–9 |year=2007 |month=August |pmid=17684766 |doi=10.1007/s00428-007-0445-0 |url=}}</ref> | ||
===Major types (primary)=== | ===Major types (primary)=== | ||
Revision as of 02:13, 30 May 2010
Lung tumours comes to pathology to get diagnosed. This article basically deals with core biopsies. Pulmonary cytopathology is dealt with in the pulmonary cytopathology article.
An introduction to lung pathology is found in the pulmonary pathology article.
Lung tumours overview
Schematic overview of lung cancer (clinical)
| Lung cancer | |||||||||||||||||||||||||||||||||||||||||
| Primary | Metastatic | ||||||||||||||||||||||||||||||||||||||||
| NSCLC | SCLC | ||||||||||||||||||||||||||||||||||||||||
- NSCLC = non-small cell lung cancer.
- SCLS = small cell lung cancer.
Basic pathologic approach to lung cancer
| Lung cancer | |||||||||||||||||||||||||||||||
| Adenocarcinoma | Squamous cell carcinoma | SCLC | LCLC | ||||||||||||||||||||||||||||
- LCLC = large cell lung cancer.
- SCLS = small cell lung cancer.
Notes:
- Most lung cancer fits into one of the above categories.
- All types may be metastatic. Pathologists usually don't have to sort this out, as the clinican often knows whether a given lesion is metastatic (when correlated with radiology).
- Lung cancers may have a mixed morphology, e.g. SCLS may have squamous component.[1]
Major types (primary)
Mnemonic ASSL:
- Adenocarcinoma.
- Squamous cell carcinoma.
- Small cell carcinoma (SCLC).
- Large cell carcinoma (LCLC).
Epidemiology
- Adenocarcinoma is the most common (primary lung cancer).[2]
- Adenocarcinoma is the non-smoker tumour - SCLC and squamous are more strongly associated with smoking.
Distribution
- Distribution - think about the location of letters in mnemonic ASSL.
- Adenocarcinoma is usually periperal, i.e. smaller airways.
- Squamous cell carcinoma and small cell carcinoma are typically central.
Management of primary lung cancer
Management is currently determined by categorization into:
- Small cell cancer.
- Non-small cell cancer (includes adenocarcinoma, squamous cell carcinoma, large cell carcinoma).
Microscopic features overview
Adenocarcinoma
- Glands or cytoplasm with mucin.
Squamous cell carcinoma
- Distinct cell borders with intercellular bridges.
- Eosinophilic cytoplasm.
Small cell carcinoma
- Very cellular.
- Large NC ratio - very small amount of cytoplasm.
- Cells fragile - they tend to look "smudged" (Azzopardi phenomenon).
IHC
There is a great review paper by Jagirdar.[3]
Small cell carcinoma
- CD56 +ve - sensitive.[4]
- CK7 -ve, CK20 -ve.
Note:
- CD56 - cytoplasmic.[5]
Squamous cell carcinoma
- CK7 -ve, CK20 -ve.
- HMWK +ve.
- Usually TTF-1 -ve.[6]
Primary vs. secondary
- TTF-1 is considered useful.[3]
- 75% +ve adenocarcinoma
- 11% +ve SSC
- 50% +ve large cell carcinoma
- 0% +ve mesothelioma
- significant rates of +ve in some metastatic tumours -- see article by Jagirdar.
Note:
- TTF-1 - should be nuclear staining; cytoplasmic staining is non-specific.[7]
Mesothelioma
Locations
- Lung.
- Primary peritoneal.
Epidemiology
- Associated with asbestos exposure.
Microscopy
- Ferruginous body (AKA asbestos body).[8]
- Made of asbestos fiber.
- Looks like a (twirling) baton.
Images:
IHC
- Several panel exists - no agreed upon best panel.[9]
- Usually two carcinoma markers + two mesothelial markers.
Panel:[9]
- Mesothelial markers:
- Calretin.
- WT-1.
- D2-40.
- CK5/6.
- Carcinoma markers:
- CEA.
- TTF-1.
See also
- Lung - introduction to the lung, includes a basic approach.
- Medical lung disease.
- Thyroid.
- Basics.
- Heart.
References
- ↑ Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M (August 2007). "Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data". Virchows Arch. 451 Suppl 1: S51–9. doi:10.1007/s00428-007-0445-0. PMID 17684766.
- ↑ Lutschg JH (January 2009). "Lung cancer". N. Engl. J. Med. 360 (1): 87-8; author reply 88. doi:10.1056/NEJMc082208. PMID 19118313.
- ↑ 3.0 3.1 Jagirdar J (March 2008). "Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung". Arch. Pathol. Lab. Med. 132 (3): 384-96. PMID 18318581. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=384.
- ↑ Hiroshima K, Iyoda A, Shida T, et al (October 2006). "Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis". Mod. Pathol. 19 (10): 1358-68. doi:10.1038/modpathol.3800659. PMID 16862075.
- ↑ URL: http://jcp.bmjjournals.com/content/58/9/978.full. Accessed: 11 February 2010.
- ↑ Al-Zahrani IH (July 2008). "The value of immunohistochemical expression of TTF-1, CK7 and CK20 in the diagnosis of primary and secondary lung carcinomas". Saudi Med J 29 (7): 957-61. PMID 18626520.
- ↑ Compérat E, Zhang F, Perrotin C, et al. (October 2005). "Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin". Mod. Pathol. 18 (10): 1371–6. doi:10.1038/modpathol.3800422. PMID 15861215. http://www.nature.com/modpathol/journal/v18/n10/full/3800422a.html.
- ↑ http://medical-dictionary.thefreedictionary.com/asbestos+body
- ↑ 9.0 9.1 Marchevsky AM (March 2008). "Application of immunohistochemistry to the diagnosis of malignant mesothelioma". Arch. Pathol. Lab. Med. 132 (3): 397-401. PMID 18318582. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=397.